AlCana Technologies

By Doug Macron
AlCana Technologies last month denied that its researchers violated non-compete agreements with their former employer, Tekmira Pharmaceuticals, as part of a legal claim filed against it by that company.

According to Tekmira, AlCana is an “instrument of Alnylam” used to “escape the licensing and royalty obligations” of the companies' agreements.

Under the terms of the research alliance, which was forged in 2009, Alnylam has the exclusive rights to all new inventions in the RNAi field, as well as rights to sublicense any resulting intellectual property to Alnylam's current and future partners.

Alnylam will have the exclusive rights to all new inventions resulting from the alliance, as well as the rights to sublicense any related intellectual property. Tekmira will have the right to use new inventions with its own RNAi therapeutics.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.